DBV Technologies S.A. (NASDAQ:DBVT) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of DBV Technologies S.A. (NASDAQ:DBVT) have earned an average recommendation of “Moderate Buy” from the eight research firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, four have given a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $48.50.

DBVT has been the topic of several research analyst reports. Guggenheim reaffirmed a “buy” rating and set a $51.00 price objective on shares of DBV Technologies in a research note on Monday, May 4th. Citizens Jmp raised their price target on DBV Technologies from $47.00 to $55.00 and gave the stock a “market outperform” rating in a research report on Friday, May 1st. Wall Street Zen raised DBV Technologies from a “sell” rating to a “hold” rating in a research report on Saturday, May 2nd. Finally, Citigroup restated an “outperform” rating on shares of DBV Technologies in a report on Friday, May 1st.

Institutional Investors Weigh In On DBV Technologies

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Perceptive Advisors LLC acquired a new stake in shares of DBV Technologies in the 1st quarter valued at about $20,146,000. Vivo Capital LLC raised its stake in shares of DBV Technologies by 8.4% in the 1st quarter. Vivo Capital LLC now owns 2,667,569 shares of the company’s stock valued at $55,726,000 after purchasing an additional 205,943 shares during the period. ADAR1 Capital Management LLC acquired a new stake in shares of DBV Technologies in the 1st quarter valued at about $21,159,000. Royal Bank of Canada raised its stake in shares of DBV Technologies by 167.1% in the 1st quarter. Royal Bank of Canada now owns 4,680 shares of the company’s stock valued at $98,000 after purchasing an additional 2,928 shares during the period. Finally, Elmind Capital LP acquired a new stake in shares of DBV Technologies in the 1st quarter valued at about $5,536,000. 71.74% of the stock is currently owned by institutional investors and hedge funds.

DBV Technologies Stock Performance

DBVT opened at $16.54 on Friday. The firm’s fifty day moving average is $19.48 and its two-hundred day moving average is $19.65. The firm has a market cap of $979.33 million, a PE ratio of -3.71 and a beta of -0.99. DBV Technologies has a twelve month low of $8.50 and a twelve month high of $26.18.

DBV Technologies (NASDAQ:DBVT) last issued its quarterly earnings data on Thursday, April 30th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.42). The business had revenue of $0.90 million for the quarter, compared to analyst estimates of $1.11 million. DBV Technologies had a negative return on equity of 129.88% and a negative net margin of 2,895.37%. Equities analysts forecast that DBV Technologies will post -0.47 EPS for the current fiscal year.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.